Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021

Rhea-AI Summary

Werewolf Therapeutics, a biopharmaceutical company listed on Nasdaq as HOWL, announced that its CEO, Daniel J. Hicklin, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 3rd at 11 am ET. The company focuses on engineering conditionally activated therapeutics to enhance the immune system for cancer treatment. Their proprietary PREDATOR™ platform aims to create molecules that activate specifically in the tumor microenvironment. WTX-124 and WTX-330 are two leading candidates currently in preclinical studies.

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET.

Access to the live webcast of this event, as well as an archived recording, will be available under the “Events” tab on the investor relations section of the Werewolf Therapeutics website at: https://investors.werewolftx.com/news-and-events/events.

About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Alan Lada
Solebury Trout
617.221.8006
alada@soleburytrout.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
elubman@werewolftx.com

FAQ

When is Werewolf Therapeutics presenting at the Jefferies Virtual Healthcare Conference?

Werewolf Therapeutics will present on June 3rd at 11 am ET.

What is the primary focus of Werewolf Therapeutics?

Werewolf Therapeutics is focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.

What are the leading product candidates of Werewolf Therapeutics?

The leading candidates are WTX-124 and WTX-330, which are designed for the treatment of solid tumors.

Where can I watch the presentation by Werewolf Therapeutics?

The presentation will be available via live webcast on Werewolf Therapeutics' investor relations website.

What unique platform does Werewolf Therapeutics use for its drug development?

The company uses the PREDATOR™ platform to engineer conditionally activated therapeutics.